tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Abivax SA (DE:2X1)
FRANKFURT:2X1
Germany Market
2X1
Abivax SA
Overview
Analyst Forecasts
Dividends
Earnings
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

Abivax SA (2X1) Stock News & Sentiment

Compare
1 Followers
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
20h ago
0RA9
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
3d ago
0RA9
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
Premium
Ratings
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
22d ago
ABVX
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
Premium
Ratings
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
23d ago
ABVX
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
Premium
Ratings
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
1M ago
ABVX
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
Premium
Ratings
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
1M ago
ABVX
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
Premium
Ratings
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
2M ago
ABVX
More DE:2X1 News >

2X1 News on the Web

Private equity firms who hold 46% of ABIVAX Société Anonyme (EPA:ABVX) gained 561%, institutions profited as well
Simply Wall St
Neutral
LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)
TipRanks News
Neutral
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)
TipRanks News
Neutral
Guggenheim Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
TipRanks News
Neutral
Abivax SA (0RA9) Receives a Buy from Kepler Capital
TipRanks News
Neutral
Abivax SA (0RA9) Receives a Buy from Kepler Capital
TipRanks News
Neutral
Health Check: How Prudently Does ABIVAX Société Anonyme (EPA:ABVX) Use Debt?
Simply Wall St
Neutral
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DE:2X1
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week59%
Sector Average55%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:2X1’s Media Buzz Sentiment?
Currently, no data Available
What is DE:2X1’s weekly average amount of articles?
Currently, no data Available
What is DE:2X1’s News Sentiment?
59% of articles about DE:2X1 were positive this week, compared to its sector average of 55%.
    Healthcare Stocks that are Trending in the News
    VREXVarex Imaging
    KMDAKamada
    OGIOrganiGram Holdings
    ARAYAccuray
    PBYIPuma Biotechnology
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing